Citations

Clear

16281 citation(s) found for "Yu, David".

Revisiting the superficial parasternal intercostal plane block: a response to Dost et al
Harbell, Monica W. , Seamans, David P. , Craner, Ryan C., Nelson, James A. , Harbell, Monica W , Craner, Ryan, Langley, Natalie R. , Nelson, James A

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 12, 2024 | Volume: 51 | Issue: 3 | Pages: 369-369

10.1136/rapm-2024-106053 | PMID 39395836 Get It

Defining ideal middle cerebral artery bifurcation aneurysm size for Woven EndoBridge embolization
Adeeb, Nimer , Aslan, Assala , Alla, Anika, McLellan, Rachel , Lay, Sovann V. , Guenego, Adrien , Renieri, Leonardo, Premat, Kévin, Möhlenbruch, Markus, Kral, Michael , Doron, Omer , Salem, Mohamed M. , Foreman, Paul M. , Vachhani, Jay A. , Shaikh, Hamza , Župančić, Vedran , Tutino, Vincent M., Mohammed, Marwa A. , Özateş, Mehmet Özgür , Ayberk, Gıyas , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M, Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios, Ulfert, Christian , Diestro, Jose Danilo Bengzon , Pukenas, Bryan , Burkhardt, Jan‐Karl , Sheth, Sunil G. , Spiegel, Gary, Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Nossek, Erez , Raz, Eytan , Killer-Oberfalzer, Monika, Asadi, Hamed , Brook, Allan , Altschul, David , Ducruet, Andrew F. , Albuquerque, Felipe C. , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Cuellar-Saenz, Hugo H., Jabbour, Pascal , Patel, Aman B. , Tutino, Vincent M. , Ibrahim, Mohamed K. , Diestro, Jose Danilo B , Shotar, Eimad , Tutino, Vincent M , Nguyen, Anh , Pero, Guglielmo , Kalousek, Vladimir , Altschul, David J , Regenhardt, Robert W , Ulfert, Christian , Lay, Sovann V , Burkhardt, Jan‐Karl , Musmar, Basel , Salim, Hamza , Cancelliere, Nicole M , Algin, Oktay , Ghozy, Sherief , Dibas, Mahmoud , Renieri, Leonardo , Carnevale, Joseph Anthony , Saliou, Guillaume , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Premat, Kévin , Möhlenbruch, Markus , Chung, Charlotte , Lylyk, Iván , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Psychogios, Marios‐Nikos , Domingo, Ricardo A. , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Essibayi, Muhammed Amir , Sheth, Sunil A., Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Siddiqui, Adnan H. , Aziz‐Sultan, Mohammad Ali , Limbucci, Nicola , Cuellar, Hugo , Jabbour, Pascal , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Journal of Neurosurgery | October 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2024.5.jns232204 | PMID 39393093 Get It

OBJECTIVE The Woven EndoBridge (WEB) device was approved to treat wide-necked bifurcation aneurysms. The device is designed as an intrasaccular flow disruptor covering aneurysm widths up to 10 mm. Although prior studies combined all aneurysm sizes, it is known that aneurysms behave differently in response to endovascular treatment based on their size. Therefore, the authors’ objective was to identify ideal middle cerebral artery (MCA) aneurysm width and neck sizes most suitable for WEB treatment. METHODS The WorldWideWEB consortium is a large multicenter retrospective database that analyzes intracranial aneurysms treated with the WEB device. In this study, all unruptured MCA bifurcation aneurysms with available measurements were included. Cutoff values based on aneurysm width and neck in relation to aneurysm occlusion status were measured using the receiver operating characteristic (ROC) curve. Propensity score matching (PSM) was then used to compare treatment outcomes between aneurysms smaller and larger than the cutoff value for both width and neck size. RESULTS The ideal cutoff values for MCA bifurcation aneurysm width and neck were 6.1 mm and 4.6 mm, respectively. On PSM, 87 matched pairs were compared based on width size (≤ 6.1 mm and > 6.1 mm), and 77 matched pairs were compared based on neck size (≤ 4.6 mm and > 4.6 mm). There was a significant difference in adequate aneurysm occlusion between aneurysms smaller and larger than those cutoff values for both widths (93% vs 76%, p = 0.0017) and neck sizes (90% vs 70%, p = 0.0026). The retreatment rate was also significantly higher for larger aneurysms in both parameters. CONCLUSIONS This study shows that MCA bifurcation aneurysms ≤ 6.1 mm in width and ≤ 4.6 mm in neck size are significantly better candidates for WEB treatment, leading to improved occlusion status and reduced retreatment rate, which are important considerations when using WEB devices.
Conservative management of brain arteriovenous malformations: results of the prospective observation registry of a pragmatic trial
Gentric, Jean-Christophe, Heppner, Jonathan, Lopez, Camille, Jabre, Roland , Bojanowski, Michel W. , Chaalala, Chiraz , Januel, Anne-Christine, Sabatier, Jean-François, Desal, Hubert, Roualdes, Vincent , Alias, Quentin , Derrey, Stéphane , Gaberel, Thomas , Barbier, Charlotte , Barreau, Xavier , Anxionnat, René , Merlot, Isabelle, Nguyen, Thanh N., Abdalkader, Mohamad , Riva, Roberto, Troude, Lucas, Ollivier, Irène , Planty-Bonjour, Alexia, Chalumeau, Vanessa, Naggara, Olivier, Lefevre, Pierre-Henri, Corre, Marine Le, Carlson, Andrew P. , Thines, Laurent, Findlay, J. Max, Chabert, Emmanuel , Zehr, Justine , Klink, Ruby , Viard, Geraldine, Magro, Elsa, _, _, Raymond, Jean , Chow, Michael M. C., Findlay, J. Max , Lesiuk, Howard , Drake, Brian , Santos, Marlene dos, Lopez, Camille, Ognard, Julien, Seizeur, Romuald, Pradier, Olivier, Boursier, Romain, Thillays, F. , Januel, Anne-Christine , Sabatier, Jean-François, Calvière, Lionel , Gauvrit, Jean‐Yves , Eugene, François, Boucherit, Julien , Lecouillard, Isabelle, Briens, Aurélien, Ronzière, Thomas , Trystram, D. , Naggara, Olivier , Emery, Évelyne , Pellisou-Guyotat, Isabelle, Guyotat, Jacques, Berhouma, Monsef, Bougaci, Nassim , Bracard, Serge, Civit, Thierry, Bernier‐Chastagner, Valérie , Penchet, Guillaume, Gimbert, Edouard, Huchet, Aymeri, Herbreteau, Denis , Bibi, Richard , Ifergan, Héloïse , Janot, Kévin, Brunel, Hervé, Roche, Pièrre-Hugues , Peyrière, Hadrien, Kaya, Jean-Marc, Touta, Adamou, Boissonneau, Sébastien , Clarençon, Frédéric , Premat, Kévin, Boch, Anne‐Laure , Cornu, Philippe, Nouet, Aurélien , Costalat, Vincent , Gascou, Gregory, Riquelme, Carlos, Pop, Raoul, Proust, François, Cébula, H. , Spatola, Giorgio, Ikka, Léon , Ozanne, Augustin , Caroff, Jildaz , Rouchaud, Aymeric, Caire, François, Ricolfi, F. , Thouant, Pierre, Cao, Catherine, Mourier, Klaus-Luc, Farah, Walid, Silva, Luciana Alves Oliveira, Froio, Nayara de Lima, Mont’Alverne, Francisco J. A., Martins, Jose Luri, Miranda, Rodrigo Rivera, Rivera, Rodrigo , Ognard, Julien , Shotar, Eimad , Ognard, Julien , Darsaut, Tim E. , Iancu, Daniela , Roy, Daniel C. , Weill, Alain , Comby, Pierre‐Olivier , Roberge, David , Cognard, Christophe , Desal, Hubert , Ferré, Jean‐Christophe , Papagiannaki, Chrysanthi , Smajda, Stanislas , Aldéa, Sorin , Marnat, Gaultier , Jecko, Vincent , Dumot, Chloé , Riva, Roberto , Graillon, Thomas , Troude, Lucas , Kerleroux, Basile , Beaujeux, Rémy , Boulouis, Grégoire , Spelle, Laurent , Chalumeau, Vanessa , Lefèvre, Pierre-Henri , Corre, Marine Le, Shotar, Eimad , Biondi, Alessandra , Tawk, Rabih G. , Huynh, Thien , Fahed, Robert , Gévry, Guylaine , _, _, O'Kelly, Cian J , Rempel, Jeremy L , Santos, Marlene dos, Gentric, Jean‐Christophe , Lopez, Camille, Nonent, Michel , Aouni, Mourad Cheddad El , Timsit, Serge , Piotin, Michel , Blanc, Raphaël , Morandi, Xavier , Vannier, Stéphane , Rodriguez-Régent, Christine , Touzé, Emmanuel , Eker, Omer , Charbonnier, Guillaume , Gory, Benjamin , Velut, Stéphane , Sourour, Nader Antoine , Lenck, Stéphanie , Premat, Kévin , Bonafé, Alain , Dargazanli, Cyril , Gascou, Grégory , Corre, Marine Le, Gallas, Sophie , Mihalea, Cristian , Mounayer, Charbel , Thouant, Pierre , Nguyen, Thanh N. , Silva, Gisele Sampaio , Montalverne, Francisco Jose , Mendes, George Nilton Nunes

Mayo Clinic

Journal of Neurosurgery | October 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.3171/2024.5.jns24623 | PMID 39393100 Get It

OBJECTIVE Many patients recruited in the Treatment of Brain Arteriovenous Malformations Study (TOBAS) are managed conservatively. The aim of this study was to monitor what happened to those patients. METHODS TOBAS comprises two randomized controlled trials and multiple prospective registries. All patients with brain arteriovenous malformations (AVMs) can participate. This report concerns patients selected for conservative management. The primary trial outcome measure is related death or dependency (modified Rankin Scale [mRS] score > 2) at 10 years. Secondary outcomes include intracranial hemorrhages, nonhemorrhagic neurological events, and serious adverse events (SAEs). For this report, outcome results are presented using patient-years, Kaplan-Meier survival curves, and Cox log-rank tests. There was no blinding. RESULTS From June 2014 to May 2021, 1010 patients were recruited, of whom 498 (49%) were proposed the prospective observation registry. After exclusions, 434 (87%) patients remained for analysis. The majority of patients had unruptured AVMs (378/434 [87%]), of which 195 (52%) were low grade (Spetzler-Martin grade I or II). During a mean follow-up period of 3.2 years (total 1368 patient-years), the primary outcome occurred in 23 of 434 (5%) patients, corresponding to an incidence of 1.7 (95% CI 1.1–2.5) per 100 patient-years. For unruptured AVMs the incidence was 1.1 (95% CI 0.7–1.9) per 100 patient-years, and for low-grade unruptured AVMs it was 0.6 (95% CI 0.2–1.7) per 100 patient-years. Poor outcomes were more frequent in patients with a history of rupture (HR 5.6 [95% CI 2.4–13.0], p < 0.001), infratentorial AVMs (HR 2.9 [95% CI 1.1–7.3], p = 0.027), and age ≥ 55 years (HR 3.2 [95% CI 1.4–7.6], p = 0.007). Major intracranial hemorrhage occurred in 35 of 434 (8%) patients (incidence of 2.6 [95% CI 1.9–3.6] per 100 patient-years; 2.0 [95% CI 1.3–2.9] per 100 patient-years for unruptured AVMs and 1.3 [95% CI 0.6–2.6] per 100 patient-years for low-grade unruptured AVMs). Major AVM hemorrhages were more frequent in ruptured (HR 4.4 [95% CI 2.1–8.9], p < 0.001), large (HR 2.6 [95% CI 1.1–6.6], p = 0.039), and high-grade (HR 2.5 [95% CI 1.2–5.3], p = 0.013) AVMs and those with deep venous drainage (HR 2.1 [95% CI 1.1–4.2], p = 0.032). SAEs occurred in 48 of 434 (11%) patients (incidence of 3.6 [95% CI 2.7–4.8] per 100 patient-years). For unruptured AVMs the incidence was 2.8 (95% CI 2.0–4.0) per 100 patient-years, and for low-grade unruptured AVMs it was 1.8 (95% CI 1.0–3.2) per 100 patient-years. CONCLUSIONS Nearly half of TOBAS participants were observed. Rates of untoward neurological events were within expected boundaries.
Can the clot meniscus and claw signs predict thrombectomy and clinical outcomes in patients with stroke? A systematic review and meta-analysis
Cortese, Jonathan , Ghozy, Sherief , Gajjar, Aryan , Douri, Dani, Kadirvel, Ramanathan , Kallmes, David F. , Reda, Abdullah , Cortese, Jonathan , Ghozy, Sherief , Kadirvel, Ram , Reda, Abdullah

Mayo Clinic

Journal of NeuroInterventional Surgery | October 11, 2024 | Volume: 17 | Issue: 9 | Pages: 932-938

10.1136/jnis-2024-022322 | PMID 39393916 Get It

Background The angiographic shape of an occlusion, like the clot meniscus sign and the claw sign, has been reported to potentially impact the recanalization rate and clinical outcome in patients undergoing mechanical thrombectomy for acute ischemic strokes. Method Following PRISMA guidelines, a systematic literature search was conducted across PubMed, Scopus, Embase and Web of Science databases. Patients were grouped into clot meniscus/claw sign positive and negative groups based on the definitions obtained from each study. Primary outcomes included technical success, with a meta-analysis performed using a random-effects model to calculate proportions and odds ratios (OR) with 95% confidence intervals (Cl). Results We included seven studies recruiting 1572 patients. The results indicated that the positive and negative groups had comparable first-pass effect (OR 1.95; 95% CI 0.76 to 5.01; P=0.167) and final recanalization (OR 1.36; 95% CI 0.81 to 2.27; P=0.248) rates. However, the rate of having a favorable functional outcome was significantly higher in the positive group than in the negative sign group (OR 1.91; 95% CI 1.25 to 2.92; P<0.003). Within the sign-positive population, the use of contact aspiration was associated with a significantly higher rate of recanalization compared with using a stent retriever (OR 0.18; 95% CI 0.07 to 0.49; P<0.001). This result did not translate into a clinical impact, as both stent retriever and contact aspiration showed comparable rates of functional independence at 3 months (OR 0.22; 95% CI 0.02 to 2.33; P=0.210). Conclusion The presence of the clot meniscus/claw sign is not associated with recanalization outcomes after thrombectomy. However, it might be a good sign to predict which thrombectomy technique might be associated with better recanalization, although current evidence may need further confirmation.
Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta‐Analysis
Ullah, Waqas , Sandhyavenu, Harigopal , Taha, Amro , Gowda, Smitha Narayana , Mukhtar, Maryam , Polam, Aravind Reddy , Zahid, Salman , Fischman, David L. , Savage, Michael P. , Rao, Sunil V. , Reddy Polam, Aravind , Alkhouli, Mohamad , Mukhtar, Maryam , Rao, Sunil V , Fischman, David , Sandhyavenu, Harigopal , Alkhouli, Mohamad

Mayo Clinic

Journal of the American Heart Association | October 11, 2024 | Volume: 13 | Issue: 20 | Pages: No page available

10.1161/jaha.122.032490 | PMID 39392170 Get It

Background Optimal duration and choice of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention remain controversial. Methods and Results Digital databases (PubMed, Cochrane, and Embase) were queried to select all randomized controlled trials on a post–percutaneous coronary intervention population with acute coronary syndrome. Dual‐antiplatelet therapy (DAPT) with aspirin and clopidogrel for 12 months was compared with 4 major strategies: high‐potency, high‐ to low‐potency, low‐dose, and short‐duration DAPT. A network meta‐analysis was performed to compare the safety and efficacy of different antiplatelet strategies. This study was the second updated manuscript under the International Prospective Register of Systematic Review registration (CRD42021286552). Thirty‐two randomized controlled trials comprising 103 459 (51 750 experimental, 51 709 control) patients were included. Compared with DAPT with aspirin and clopidogrel for 12 months, high‐ to low‐potency DAPT (risk ratio [RR], 0.69 [95% CI, 0.52–0.92]) and aspirin+prasugrel containing DAPT for 12 months (RR, 0.84 [95% CI, 0.72–0.98]) had a significantly lower, whereas DAPT for 1 month followed by clopidogrel only (RR, 1.59 [95% CI, 1.06–2.39]) had a higher, incidence of major adverse cardiovascular events at 1 year (median follow‐up). Prasugrel (RR, 1.35 [95% CI, 1.09–1.66]) and ticagrelor (RR, 1.38 [95% CI, 1.17–1.62]) containing DAPT for 12 months had significantly higher rates, whereas high‐ to low‐potency DAPT (RR, 0.85 [95% CI, 0.63–1.15]) had no significant risk of major bleeding. Conclusions Aspirin and ticagrelor for 3 months, followed by aspirin and clopidogrel for the remaining duration, can be considered the optimal strategy for treating post–percutaneous coronary intervention patients with acute coronary syndrome because of a significantly reduced risk of major adverse cardiovascular events without increasing the risk of bleeding.
Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers
Lowe, Val J. , Mester, Carly , Lee, Jeyeon , Ghatamaneni, Sujala, Algeciras‐Schimnich, Alicia , Campbell, Michelle R. , Graff‐Radford, Jonathan , Nguyen, Aivi T. , Min, Hoon‐Ki , Kandimalla, Karunya K. , Kantarci, Kejal, Jack, Clifford R. , Petersen, Ronald C. , Kantarci, Kejal , Algeciras-Schimnich, Alicia , Mester, Carly T, Lundt, Emily S. , Min, Hoon-Ki Paul , Jack, Clifford R , Kantarci, Kejal , Kandimalla, Karunya K , Nguyen, Aivi T , Senjem, Matthew L. , Machulda, Mary M. , Schwarz, Christopher G. , Dickson, Dennis W. , Murray, Melissa E. , Boeve, Bradley F. , Vemuri, Prashanthi , Jones, David T. , Knopman, David S. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | October 11, 2024 | Volume: 20 | Issue: 11 | Pages: 8097-8112

10.1002/alz.14317 | PMID 39392211 Get It

AbstractINTRODUCTIONUnderstanding the relationship between amyloid beta (Aβ) positron emission tomography (PET) and Aβ cerebrospinal fluid (CSF) biomarkers will define their potential utility in Aβ treatment. Few population‐based or neuropathologic comparisons have been reported.METHODSParticipants 50+ years with Aβ PET and Aβ CSF biomarkers (phosphorylated tau [p‐tau]181/Aβ42, n = 505, and Aβ42/40, n = 54) were included from the Mayo Clinic Study on Aging. From these participants, an autopsy subgroup was identified (n = 47). The relationships of Aβ PET and Aβ CSF biomarkers were assessed cross‐sectionally in all participants and longitudinally in autopsy data.RESULTSCross‐sectionally, more participants were Aβ PET+ versus Aβ CSF− than Aβ PET− versus Aβ CSF+ with an incremental effect when using Aβ PET regions selected for early Aβ deposition. The sensitivity for the first detection of Thal phase ≥ 1 in longitudinal data was higher for Aβ PET (89%) than p‐tau181/Aβ42 (64%).DISCUSSIONAβ PET can detect earlier cortical Aβ deposition than Aβ CSF biomarkers. Aβ PET+ versus Aβ CSF− findings are several‐fold greater using regional Aβ PET analyses and in peri‐threshold‐standardized uptake value ratio participants.Highlights Amyloid beta (Aβ) positron emission tomography (PET) has greater sensitivity for Aβ deposition than Aβ cerebrospinal fluid (CSF) in early Aβ development. A population‐based sample of participants (n = 505) with PET and CSF tests was used. Cortical regions showing early Aβ on Aβ PET were also used in these analyses. Neuropathology was used to validate detection of Aβ by Aβ PET and Aβ CSF biomarkers.
Comparison of brief olfactory and cognitive assessments to neuroimaging biomarkers in the prediction of cognitive decline and dementia in the MCSA cohort
Devanand, Davangere P. , Lee, Seonjoo , Vassilaki, Maria , Motter, Jeffrey N. , Luchsinger, Jose Alejandro , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | October 10, 2024 | Volume: 20 | Issue: 12 | Pages: 8346-8358

10.1002/alz.14261 | PMID 39387454 Get It

AbstractINTRODUCTIONWe evaluated impaired odor identification and global cognition as simple, cost‐effective alternatives to neuroimaging biomarkers to predict cognitive decline and dementia in the Mayo Clinic Study of Aging.METHODSSix hundred forty‐seven participants (mean 8.1, standard deviation 3.4 years’ follow‐up) had the following baseline procedures: modified Blessed Information Memory Concentration Test (BIMCT), 12‐item Brief Smell Identification Test (BSIT), structural brain magnetic resonance imaging (MRI), and positron emission tomography (PET) imaging with 11C‐Pittsburgh compound B (11C‐PiB) and fluorodeoxyglucose (FDG; subset).RESULTSCognitive decline developed in 102 participants and dementia in 34 participants. In survival analyses, PiB PET showed robust prediction for cognitive decline. Impaired BSIT, impaired BIMCT, MRI, and FDG measures were also significant predictors. The combination of demographics + BSIT + BIMCT showed strong predictive utility (C‐index 0.81), similar to demographics + PiB PET (C‐index 0.80). Similar but stronger results were obtained for prediction of dementia.DISCUSSIONImpairment in both odor identification test and global cognition was comparable to PiB PET for predicting cognitive decline and dementia.Highlights In 647 participants in the population‐based Mayo Clinic Study of Aging, several clinical markers and biomarkers each predicted cognitive decline or dementia during an average 8 years of follow‐up. The combination of the demographic variables of age, sex, and education with a brief odor identification test (BSIT) and a global cognitive test (Blessed Information Memory Concentration Test) showed strong predictive utility (C‐index 0.81) for cognitive decline that was similar to the demographic variables combined with Pittsburgh Compound B amyloid imaging (C‐index 0.80). Combining a brief odor identification test with a brief cognitive test needs consideration as a simple, cost‐effective option in the clinical assessment of individuals at risk of cognitive decline and dementia, as well as a potential tool to identify individuals who may benefit from disease‐modifying treatments and to screen participants for prevention trials.
Rapid and Accurate Diagnosis and Prognosis of Acute Infections and Sepsis from Whole Blood Using Host Response mRNA amplification and Result Interpretation by Machine-Learning Classifiers
Liesenfeld, Oliver , Arora, Sanjay , Aufderheide, T. P., Fischer, Miriam, Giamarellos‐Bourboulis, Evangelos J. , House, Stacey L. , Humphries, Roger L., Liu, Edward , Mace, Sharon E. , May, Larissa, Michelson, Edward A. , Panacek, Edward A., Self, Wesley H. , Smithline, Howard , Steingrub, Jay S. , Heukelom, Paul Van , Weissman, Alexandra , Wolk, Donna M. , Buturović, Ljubomir , Damaraju, Nandita , Lu, Cici, Whitfield, Natalie N. , Shapiro, Nathan I. , Giamarellos-Bourboulis, Evangelos J , Aufderheide, Tom P. , Clements, Casey M. , DeVos, Elizabeth , Fischer, Miriam, Gill, Jasreen Kaur , Osborn, Tiffany Medlin , Rothman, Richard Eric , Wilson, Matthew, Wright, David W. , Hasin-Brumshtein, Yehudit , Shak, Joshua R., Khatri, Purvesh , Sweeney, Timothy E.

Mayo Clinic

No container title available | October 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5194992/v1 Get It

Abstract Many patients in the emergency department present with signs and symptoms that arouse concern for sepsis; however, other explanations are also possible. There are currently no rapid tests used in clinical practice that reliably distinguish the presence of a bacterial or viral infection vs. a non-infectious etiology and can predict a patient’s likelihood to decompensate. The diagnostic and prognostic uncertainty in “gray zone” patients complicates the decision to begin therapy as clinicians need to balance the risk of withholding therapy vs. the risk of the therapy itself (e.g., overtreatment with antibiotics and hospitalization, which is costly, potentially harmful, and contributes to antibiotic resistance). The TriVerity™ Test uses isothermal amplification and machine-learning algorithms to quantify and interpret mRNA expression levels to determine both likelihood of bacterial infection, viral infection, or no infection, and whether the patient will likely require one or more critical interventions within 7 days. The three scores each fall into one of five interpretation bands ranging from Very high to Very low. Testing takes approximately 30 minutes using the proprietary Myrna™ Instrument with an operator hands-on-time of under one minute. We enrolled 1,222 patients from 22 emergency departments (ED) to validate the performance of the TriVerity Test. Patients were treated as per local standard of care and were followed for 28 days. Bacterial and viral TriVerity results were validated against clinically adjudicated infection status; the illness severity TriVerity result was validated against the need for at least one critical interventions within 7 days. The bacterial TriVerity result had high AUROC for the diagnosis of bacterial infection (0.83; 80% CI 0.81–0.85) and divided bacterial infection likelihood scores into five interpretation bands with increasing likelihood ratios of infection ranging from Very low (LR- 0.08, 80% CI 0.06–0.11) to Very high (LR + 8.04, 80% CI 5.72–11.78). The AUROC for the bacterial TriVerity result was significantly higher compared to AUROCs for C-reactive protein, procalcitonin or white blood cell count. Similarly, the viral TriVerity score showed high AUROC for the diagnosis of viral infection (0.91; 80% CI 0.90–0.93) and likelihood ratios from Very low (LR- 0.09, 80% CI 0.05–0.14) to Very high (LR + 40.93; 80% CI 29.11–79.23). The TriVerity Illness Severity score showed a high AUROC for the prediction of illness severity (0.77; 80% CI 0.77–0.81) with scores divided into five interpretation bands with increasing likelihood ratios ranging from Very low (LR- 0.22; 80% CI 0.14–0.33) to Very high (LR + 11.33; 80% CI 7.31–17.00). TriVerity illness severity results allowed marked re-classification of the risk for “ICU-level care” as compared to clinical assessment (qSOFA scores) alone. In conclusion, TriVerity provides rapid, highly accurate and actionable results for the diagnosis and prognosis of patients with suspected acute infection and/or sepsis, supporting a major unmet medical need. TriVerity may improve personalized management of patients with suspected acute infections and suspected sepsis for improved overall healthcare outcomes.
A Tale of 102,726 Messages: Characterizing the Modern Urologist's Portal Message Burden After Common Urologic Surgeries
Warren, Christopher J. , Mauler, David J. , Butterfield, Duke, Wymer, Kevin , Khan, Aqsa , Humphreys, Mitchell R. , Tyson, Mark D. , Mauler, David, Punjani, Nahid

Mayo Clinic

Urology Practice | October 9, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/upj.0000000000000718 | PMID 39383007 Get It

Early Renal Outcomes Following Heart Transplantation Using Organs Procured After Circulatory Death
Zhou, Joyce , Sise, Meghan E. , Drezek, Kamila , Wolfe, Stanley B. , Osho, Asishana A. , Prario, Monica N. , Rabi, S. Alireza , Michel, E., Tsao, Lana, Coglianese, Erin , Doucette, Meaghan, Newton‐Cheh, Christopher , Thomas, Sunu, Sutaria, Nilay, Schoenike, Mark, Christ, Anastasia M. , Villavicencio, Mauricio A. , Madsen, Joren C. , Pierson, Richard N. , D’Alessandro, David A. , Zhou, Joyce C , Ton, Van-Khue , Christ, Anastasia M , Paneitz, Dane C , Villavicencio, Mauricio, Madsen, Joren C , Pierson, Richard , Lewis, Gregory D , D'Alessandro, David A , Zlotoff, Daniel A , Wolfe, Stanley , Osho, Asishana , Michel, Eriberto , Ton, Van‐Khue , Lewis, Gregory D.

Mayo Clinic

Journal of the American Heart Association | October 8, 2024 | Volume: 13 | Issue: 20 | Pages: No page available

10.1161/jaha.124.035443 | PMID 39377217 Get It

Background Transplantation using hearts obtained through donation after circulatory death (DCD) is increasing, but data on recipient renal outcomes are limited. Methods and Results Patients at a single institution who underwent heart transplantation using organs procured through DCD or donation after brain death (DBD) from April 2016 to August 2022 were included in this retrospective cohort study. Hemodynamic measures were collected via right heart catheterization performed 1 week after transplantation. Posttransplantation renal outcomes included estimated glomerular filtration rate at 1 week, 4 weeks, and 16 weeks, and the incidence of acute kidney injury (AKI) and renal replacement therapy within 1 week. The analysis included 225 patients (55 recipients of DCD). Baseline characteristics were comparable between recipients of DCD and DBD. Renal outcomes within 1 week posttransplantation in recipients of DCD were similar to recipients of DBD, including percent change in estimated glomerular filtration rate (−37.9% [−58.6 to −6.2] versus −31.9% [−52.4 to −9.9]; P =0.91), incidence of AKI (47.3% versus 46.5%; P >0.99) and incidence of renal replacement therapy (3.6% versus 4.7%; P >0.99). Recipients of DCD with AKI within 1 week (“early AKI”) did not recover to baseline estimated glomerular filtration rate (75.8 [60.2–91.3] mL/min per 1.73 m 2 ) by week 16 (59.3 [46.9–73.6] mL/min per 1.73 m 2 ; P =0.002), whereas recipients without early AKI exhibited comparable estimated glomerular filtration rate to baseline by week 4 (84.5 [70.8–98.5] mL/min per 1.73 m 2 ; P =0.084). Similar trends were observed in recipients of DBD. Conclusions Recipients of DCD demonstrated similar renal outcomes compared with recipients of DBD, supporting the ongoing use of DCD transplantation. Early AKI was associated with persistent renal dysfunction for recipients of both DCD and DBD.